ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily trading volume, of 389,200 shares, the days-to-cover ratio is presently 8.0 days. Approximately 11.5% of the shares of the company are sold short.

ALX Oncology Price Performance

NASDAQ:ALXO traded down $0.14 during trading hours on Monday, reaching $12.89. The company had a trading volume of 328,155 shares, compared to its average volume of 393,840. The stock has a 50-day moving average of $13.52 and a two-hundred day moving average of $11.77. ALX Oncology has a one year low of $3.94 and a one year high of $17.42. The firm has a market capitalization of $646.43 million, a PE ratio of -3.44 and a beta of 1.58. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.05.

ALX Oncology (NASDAQ:ALXO) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). Analysts forecast that ALX Oncology will post -3.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of ALX Oncology in a research report on Wednesday, April 10th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Friday. Finally, Stifel Nicolaus restated a “hold” rating and set a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.83.

Insider Transactions at ALX Oncology

In other ALX Oncology news, CEO Jason Lettmann purchased 4,400 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was bought at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the acquisition, the chief executive officer now directly owns 171,620 shares in the company, valued at $1,941,022.20. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Jaume Pons sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00. Following the sale, the insider now directly owns 628,359 shares in the company, valued at $7,006,202.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Jason Lettmann acquired 4,400 shares of the stock in a transaction dated Thursday, March 14th. The shares were purchased at an average price of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the transaction, the chief executive officer now owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Corporate insiders own 50.30% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in ALX Oncology by 49.0% in the fourth quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock worth $22,371,000 after purchasing an additional 494,173 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of ALX Oncology during the fourth quarter valued at $1,201,000. American International Group Inc. lifted its stake in shares of ALX Oncology by 24.1% during the fourth quarter. American International Group Inc. now owns 13,398 shares of the company’s stock valued at $199,000 after acquiring an additional 2,600 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of ALX Oncology during the fourth quarter valued at $8,090,000. Finally, Legal & General Group Plc lifted its stake in shares of ALX Oncology by 42.6% during the fourth quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after acquiring an additional 684 shares during the period. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.